It was the aim of this study to test for a possible effect of the new non ergot dopamine agonist CV 205–502 on plasma growth hormone(GH) concentrations in acromegaly.Plasma growth hormone concentrations decreased by 48.8±8.7 %. The nadir was observed 3 hours after CV 205–502 was administered and GH concentrations remained suppressed throughout the 7 hours of the test period. In contrast GH plasma concentrations in the control group remained stable.We conclude that acute administration of CV 205–502 supresses GH secretion in acromegalic patients and thus could serve as an alternative therapy in acromegaly.10 acromegalic patients received a single oral dose of 150μg CV 205–502 after an overnight fast. As a control group 7 acromegalic patients undertook the same procedure without receiving any drug. Blood samples were drawn hourly up to 7 hours thereafter for determination of GH.